Trials / Unknown
UnknownNCT05970822
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
A Phase 1b Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of BC3402 in Combination With Azacitidine in Subjects With Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Biocity Biopharmaceutics Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of BC3402 in combination with azacitidine (AZA) in subjects with Myelodysplastic Syndrome (MDS) and Chronic myelomonocytic leukemia (CMML)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BC3402 | Escalating of BC3402 will be administered IV(intravenous) |
| DRUG | Azacitidine | Azacitidine will be administered daily |
Timeline
- Start date
- 2023-06-18
- Primary completion
- 2025-03-01
- Completion
- 2025-12-01
- First posted
- 2023-08-01
- Last updated
- 2023-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05970822. Inclusion in this directory is not an endorsement.